{"resourceType": "Evidence", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"], "versionId": "70", "lastUpdated": "2025-10-07T17:12:54.639Z"}, "identifier": [{"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}], "text": "FEvIR Object Identifier"}, "system": "https://fevir.net/FOI", "value": "236966", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "outcomeId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "313960"}, {"type": {"text": "picoId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "85798"}, {"type": {"text": "sectionId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "73215"}], "name": "End_stage_kidney_disease_from_MAGICapp_313960", "title": "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "status": "active", "author": [{"name": "Computable Publishing\u00ae: MAGIC-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ComparativeEvidence", "display": "ComparativeEvidence"}]}}], "relatesTo": [{"type": "part-of", "targetReference": {"type": "Composition", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-conversion-report", "assigner": {"display": "Computable Publishing LLC"}}, "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"}}], "variableDefinition": [{"description": "Adults with type 2 diabetes", "variableRole": "population", "observed": {"type": "Group", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-population-group-85394-85798", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Adults with type 2 diabetes and CVD and CKD", "reference": "Group/236947"}}, {"description": "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA", "variableRole": "exposure", "comparatorCategory": "GLP-1 RA", "observed": {"type": "EvidenceVariable", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-group-assignment-85394-85798", "assigner": {"display": "Computable Publishing LLC"}}, "display": "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA", "reference": "EvidenceVariable/236950"}}, {"description": "End-stage kidney disease", "variableRole": "outcome", "observed": {"type": "EvidenceVariable", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-313960", "assigner": {"display": "Computable Publishing LLC"}}, "display": "End-stage kidney disease", "reference": "EvidenceVariable/236965"}}], "synthesisType": [{"text": "SYSTEMATIC_REVIEW"}], "studyDesign": [{"coding": [{"system": "http://hl7.org/fhir/study-design", "code": "SEVCO:01003", "display": "randomized assignment"}]}], "statistic": [{"description": "Risk Difference -1.0% (CI95 -3.4% to 2.0%)", "statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000424", "display": "risk difference"}]}, "quantity": {"value": -0.01}, "sampleSize": {"numberOfStudies": 1, "numberOfParticipants": 463}, "attributeEstimate": [{"type": {"text": "CI95"}, "range": {"low": {"value": -0.034}, "high": {"value": 0.02}}}]}, {"description": "OR 0.91 (CI95 0.69 to 1.2)", "statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000182", "display": "odds ratio"}]}, "quantity": {"value": 0.91}, "sampleSize": {"numberOfStudies": 1, "numberOfParticipants": 463}, "attributeEstimate": [{"type": {"text": "CI95"}, "range": {"low": {"value": 0.69}, "high": {"value": 1.2}}}]}], "certainty": [{"description": "Due to serious imprecision", "type": {"coding": [{"system": "http://hl7.org/fhir/certainty-type", "code": "Overall", "display": "Overall certainty"}]}, "rating": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/27834", "code": "RJCS-2004", "display": "Moderate certainty"}]}, "subcomponent": [{"type": {"text": "Risk of Bias"}, "rating": {"text": "NOTSET"}}, {"type": {"text": "Inconsistency"}, "rating": {"text": "NOTSET"}}, {"type": {"text": "Indirectness"}, "rating": {"text": "NOTSET"}}, {"type": {"text": "Imprecision"}, "rating": {"text": "NOTSET"}}, {"type": {"text": "Publication Bias"}, "rating": {"text": "NOTSET"}}]}], "assertion": "There probably be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists.", "url": "https://fevir.net/resources/Evidence/236966", "id": "236966", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "citeAs": "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing\u00ae: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236966. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236966. Computable resource at: https://fevir.net/resources/Evidence/236966#json.", "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}